EMA Validates Gilead's Marketing Application for Sofosbuvir
Gilead Sciences, Inc. (GILD: Quote) said Tuesday that its Marketing Authorisation Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection, which was submitted to the European …
See all stories on this topic »
Malloy to address a tourism conference highlighting "Still Revolutionary" campaign
HARTFORD, Connecticut — Connecticut's “Still Revolutionary” tourism marketing campaign is succeeding and deserves continued funding, Gov. Dannel P. Malloy said Tuesday. The campaign, unveiled last year as part of a two-year, $27 million initiative, …
See all stories on this topic »
5 Reasons Why Network Marketing has a Bad Reputation. Is it …
If you've been alive long enough and have even a handful of friends, you've most likely been approached by someone building a network marketing or multi-lev.
See all stories on this topic »
Popular Questions
What does EMA validation of Gilead's marketing application for sofosbuvir mean?
Validation means the European Medicines Agency found Gilead's application complete enough to begin its formal review. It does not mean that sofosbuvir has already received marketing authorization in the European Union. The next step is an assessment of the medicine's quality, safety, and efficacy data.
Why was Gilead's marketing application for sofosbuvir submitted to the EMA?
Gilead submitted the application to seek authorization for sofosbuvir as a treatment option for people with chronic hepatitis C. The EMA review evaluates the evidence supporting the medicine and its proposed use. A positive scientific opinion would still need to precede an official European Commission authorization.
What happens after the EMA validates Gilead's application for sofosbuvir?
Following validation, the EMA's scientific committees review the clinical and manufacturing information included in the application. The agency may request additional data or clarification from Gilead during the assessment. The review concludes with a recommendation that can support or reject marketing authorization.
Does EMA validation mean sofosbuvir is approved for hepatitis C treatment?
No, EMA validation of Gilead's sofosbuvir application is an administrative milestone rather than a final approval. It confirms that the submission can enter the centralized European evaluation process. Patients and healthcare professionals must wait for the completed review and any subsequent authorization before relying on an approved European indication.